The medical research model has long been built upon a system of competition for funding (grants) and accolades (publishing). This wasn't working well for Kathy Giusti. When she was diagnosed, no treatment had been developed for multiple myeloma in decades, and what was available wasn't very effective.
Kathy realized that the old model was a barrier to success, and encouraged individuals and companies to hoard their data and discoveries. She and her sister created the MMRF to replace this system with a new patient-centered model of collaboration.
Because our only motivation is to find a cure, we are unencumbered in our ability to identify the barriers to progress, develop models to overcome them, and help evolve the industry through technologies that foster collaboration and leverage the collective power of the entire community.
This powerful MMRF philosophy has been well-proven as the most efficient way to continually speed the development of more effective treatments for patients.
Our accomplishments include:
The results are impressive. Ten drugs received FDA approval in the time it normally takes for one. More recently, we opened clinical trials for new drugs in three approved classes plus agents in many new classes.
As the world's number one private funder of multiple myeloma research, we have raised over $275 million since our inception. We direct nearly 90% of our total budget to research and related programming.
We are well-positioned to see new drug breakthroughs that will make a difference in patients' lives. And, in the process, we are changing the way cancer research is conducted.
The MMRF CoMMpassSM Study
Launched in 2011, the MMRF CoMMpass Study will be collecting tissue samples from patients over a 10-year period before treatment, at confirmed remission, and at relapse, to identify new drug targets and understand the molecular and genetic changes underpinning the disease as it evolves — and eventually match sub-types to the right treatment.LEARN MORE
The MMRF Researcher Gateway
The MMRF Researcher Gateway is a first-in-class, publicly shared database of clinical and molecular data never before made widely available for myeloma. It provides access to genomic and other information from the MMRF CoMMpass Study as it becomes available.LEARN MORE
The MMRF CoMMunity Gateway
This online platform connects patients with various subtypes of myeloma to each other and experts, and helps them find appropriate trials. It enables patients to provide important, real-time feedback about therapeutic efficacy and quality of life on treatment that will inform better clinical decisions and patient care — and deepen our understanding of myeloma.LEARN MORE
The MMRF Genomics Initiative
The most extensive research collaboration ever focused on the genomics of multiple myeloma, the MMGI collaboration was the first to map the multiple myeloma genome. The result, a centralized repository of high-quality genomic information and cutting-edge bioinformatics tools, has improved our ability to identify specific subtypes and design therapies to treat them.LEARN MORE